Blog

Careers

Advertise

Contact

logo
  • About
    • Mission
    • What Is A GPO ?
    • Policy Positions
    • HSCA Committees
    • Member Organizations
    • FAQ
    • Leadership
    • HSCA Staff
    • Contact
  • Events
    • National Pharmacy Forum 2022
    • Past Events
  • CHeS
    • CHeS Total Visibility Project
    • CHeS Membership
    • CHeS Resources
  • Issues
  • Resources
    • Studies
    • Hospital Testimonials
    • Supplier Endorsements
    • Small Supplier Portal
    • Congressional Resources
    • COVID-19 Recommendations
    • COVID-19 Response Efforts
  • News
  • About
    • Mission
    • What Is A GPO ?
    • Policy Positions
    • HSCA Committees
    • Member Organizations
    • FAQ
    • Leadership
    • HSCA Staff
    • Contact
  • Events
    • National Pharmacy Forum 2022
    • Past Events
  • CHeS
    • CHeS Total Visibility Project
    • CHeS Membership
    • CHeS Resources
  • Issues
  • Resources
    • Studies
    • Hospital Testimonials
    • Supplier Endorsements
    • Small Supplier Portal
    • Congressional Resources
    • COVID-19 Recommendations
    • COVID-19 Response Efforts
  • News

HSCA Applauds House Committee on Energy and Commerce for Commitment to Supporting Quality and Protecting Patients from Counterfeit Medical Products

March 11, 2020 by Brigid Hasson 2019 Press Releases 0 comments

Washington, DC (March 11, 2020) – Healthcare Supply Chain Association (HSCA) President and CEO Khatereh Calleja today released the following statement in conjunction with the House Committee on Energy and Commerce’s open mark-up session on the Safeguarding Therapeutics Act and twelve other bills:

“HSCA and its member group purchasing organizations (GPOs) applaud Representatives Engel, Guthrie, and all members of the House Committee on Energy and Commerce for helping to protect the healthcare supply chain by working to advance the Safeguarding Therapeutics Act. As the United States continues to address the spread of the coronavirus, strengthening the healthcare supply chain is more important than ever before. The Safeguarding Therapeutics Act enhances the U.S. Food and Drug Administration’s (FDA) authority to destroy counterfeit drugs and medical devices at American ports of entry, preventing such products from entering the supply chain and helping to ensure a safe and reliable supply of products.

Click here to read the full statement.

Prev
Next

Related Posts

HSCA Statement on Senate HELP Committee Hearing on the Coronavirus
March 3, 2020

Washington, DC (March 3, 2020) – Healthcare Supply Chain Association (HSCA)...

Learn more
Comments of the Healthcare Supply Chain Association (HSCA) on USTR Request for Comments on the Proposed Modification of Action Pursuant to Section 301
July 1, 2019

On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the...

Learn more
HSCA Submits Comments to FDA on Using Unique Device Identifiers in Medical Device Safety Communications to Support Accuracy, Quality, and Patient Safety
January 18, 2021

Washington, DC (January 19, 2021) – The Healthcare Supply Chain Association...

Learn more
HSCA Comments to the Senate HELP Committee on Planning for the Next Pandemic
June 29, 2020

Dear Chairman Alexander and Ranking Member Murray: On behalf of the...

Learn more

Our Office

Healthcare Supply Chain Association
1341 G Street NW Suite 600
Washington, DC 20005

Phone: 202.629.5833
Fax: 202.466.9666
Email: info@supplychainassociation.org

LATEST NEWS

  • HSCA Support Letter to the House Committee on Energy & Commerce on House Passage of FDA User Fee Reauthorizations
    June 30, 2022
  • ANALYSIS: GPOs Helped Increase Domestic Manufacturing Capacity, Protected Hospitals and Patients from Thousands of Fraudulent Sellers, and Helped Identify and Bring New Suppliers to Market to Avert Supply and Drug Shortages During COVID-19
    April 20, 2022